The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 6, Issue 2, 2012, Pages 129-135

  Baruah, Manash P ^a   Kalra, Sanjay ^b  

^a Excel Care Hospitals   (India)

^b BRIDE ^*  (India)

Author keywords

Basal insulin; FDC; GLP 1 analogue; GLP 1 and insulin combination; Injectable FDC; Insulin; Type 2 DM

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC PLUS LIRAGLUTIDE; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; NN 9068; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN; UNCLASSIFIED DRUG;

ADD ON THERAPY; CONTINUOUS INFUSION; DIABETIC PATIENT; DIET RESTRICTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84861771727     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221412800604563     Document Type: Review

References (54)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94(3): 311-21.
2. Odegard PS, Capoccia K. Medication taking and diabetes: A systematic review of the literature. Diabetes Educ 2007; 33(6): 1014-29.
3. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132(6): 2131-57.
4. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32(1): 193-203.
5. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, et al. AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocr Pract 2011; 17(Suppl 2): 1-53.
6. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321(7258): 405-12.
7. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005; 28(12): 2948-61.
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type II diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
9. Ansari G, Mojtahedzadeh M, Kajbaf F, Najafi A, Khajavi MR, Khalili H, et al. How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines. Adv Ther 2008; 25(7): 681-702.
10. Defelippis, M., DiMarchi, R., Ng, K. Pre-mixes of GLP-1 and basal insulin. US7238663 (2007).
11. DeFelippis, M., DiMarchi, R., Ng, K., Trautmann, M. Biphasic mixtures of GLP-1 and insulin. US7179788 (2007).
12. Liselotte, K. Combined use of derivatives of GLP-1 analogs and PPAR ligands. US20030022816 (2003).
13. Anne, P. Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and basal insulin peptide. US20110152185 (2011).
14. Svend, L. Pharmaceutical compositions containing insulin and insulinotropic peptide. US20080280814 (2008).
15. Knudsen, L.B. Use of GLP-1 compound for treatment of critically ill patients. US20030199445 (2003).
16. Coolidge, T.R., Falls, V.C.T., Ehlers, M.R.W., Mercer, I.W.A. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain. USRE41288 (2010).
17. Anderson, C. Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis. US20070021336 (2007).
18. Suad, E. Use of GLP-1 or analogs in treatment of myocardial infarction. US6277819 (2001).
19. Dennis, B.H. Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders. US6770620 (2004).
20. Richardson, P., Baughman, R.A., Costello, D. Method of preventing adverse effects by GLP-1. US20090110647 (2009).
21. Michelsen, B.K., Sturis, J. Combined use of a modulator of CD3 and a GLP-1 compound. US20080213288 (2008).
22. Tatake, R.J., O'neill, M.M., Monaco, K.-a. Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide- 1 (GLP-1), Human cells comprising said construct and insulinproducing constructs, and method of use thereof. US20110076257 (2011).
23. Full Prescribing Information of BYETTA (exenatide) Injection available at: http://pi.lilly.com/us/byetta-pi.pdf (Accessed on: February 1, 2012).
24. Barnett A. Exenatide. Expert Opin Pharmacother 2007; 8(15): 2593-608.
25. Nikfar S, Abdollahi M, Salari P. The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and metaanalysis of randomized clinical trials. J Pharm Pharmaceut Sci 2012; 15(1): 1-30.
26. Salari, P, Nikfar S, Abdollahi M. No superiority of exenatide over insulin in diabetic patients in terms of weight reduction or incidence of adverse effects: A meta-analysis. Int J Pharmacol 2011; 7(7): 749-56.
27. ® (Liraglutide). Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022341 s004lbl.pdf (Accessed on: December 9, 2011).
28. Full Prescribing Information of BYDUREON™ (exenatide extended-release for injectable suspension). Available at http://documents.bydureon.com/Bydureon_PI.pdf. (Accessed on: February 06, 2012).
29. Spellman CW. Incorporating glucagon-like Peptide-1 receptor agonists into clinical practice. J Am Osteopath Assoc 2012; 112(suppl 1): S7-S15.
30. Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes Technol Ther 2011; 13 (Suppl 1): S103-8.
31. Nauck MA, Meier JJ. Pharmacotherapy: GLP-1 analogues and insulin: Sound the wedding bells? Nat Rev Endocrinol 2011; 7(4): 193-5.
32. Data on File; Novo Nordisk India Pvt Ltd.
33. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al. Use of twice-daily exenatide in Basal insulintreated patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med 2011; 154(2): 103-12.
34. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010; 103(9): 687-94.
35. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: A proof-of-concept study. Diabetes Care 2010; 33(7): 1509-15.
36. Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O. Combination therapy with insulin glargine and exenatide: Real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin 2012; 28(2): 1-8.
37. Pawaskar MD, Blickensderfer AL, Hoogwerf BJ, Quimbo R, Wade R. Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy. J Med Econ 2011; 14(6): 705-8.
38. Levin PA, Mersey JH, Zhou S, Bromberger LA. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 Diabetes. Endocr Pract 2012; 18(1): 17-25.
39. Clinical Trial Registry. Available at: http://clinicaltrials.gov/ct2/show/record/NCT00960661?term=exenatide+%2B+glargine&rank=1(Accessed on: February 6, 2012).
40. Bain SC, DeVries JH, Seufert J, D'Alessio D, Rodbard HW, Thomsen AB, et al. Adding insulin detemir (IDet) to liraglutide and metformin improves glycaemic control with sustained weight reduction and low hypoglycemia rate: 52 Week results. Diabetologia 2011; 54 (Suppl 1): S37.
41. Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther 2011; 13(5): 592-5.
42. st Annual Meeting and Scientific Sessions of the American Diabetes Association. San Diego, USA (2011).
43. Morrow L, Hompesch M, Guthrie H, Chang D, Chatterjee DJ. Coadministration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab 2011; 13(1): 75-80.
44. st Annual Meeting and Scientific Sessions of the American Diabetes Association. San Diego, USA (2011).
45. Clinical trial registry. Available at: http://clinicaltrials.gov/ct2/show/NCT01319240?intr=%22insulin+degludec%2Fliraglutide%22&rank=3 (Accessed on: February 6, 2012).
46. Clinical trial registry. Available at: http://clinicaltrials.gov/ct2/show/NCT01336023?intr=%22insulin+degludec%2Fliraglutide %22&rank=2 (Accessed on: February 6, 2012).
47. Clinical trial registry. Available at: http://clinicaltrials.gov/ct2/show/NCT00975286?term=lixisenatide&rank=6 (Accessed on: February 6, 2012).
48. Clinical trial registry. Available at: http://clinicaltrials.gov/ct2/show/NCT01476475?term=lixisenatide&rank=8 (Accessed on: February 6, 2012).
49. Clinical trial registry. Available at: http://clinicaltrials.gov/ct2/show/NCT00866658?term=lixisenatide&rank=11 (Accessed on February 6, 2012).
50. Clinical trial registry. Available at: http://clinicaltrials.gov/ct2/show/NCT00715624?term=lixisenatide&rank=15 (Accessed on February 6, 2012).
51. US FDA Supplement approval. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021773s029,s030ltr.pdf (Accessed on February 6, 2012).
52. Outcome of extension of indication application for Victoza (liraglutide). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/001026/WC500112831.pdf (Accessed on: February 6 2012).
53. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003; 22(2): 151-85.
54. Kalra S, Ganapathi M, John M. The Exaptation of Endocrine Pharmacology. Indian J Endocrinol Metab 2012; 16: 326-7.